新闻通稿

/新闻通稿

Oramed to Present at Oppenheimer’s Annual Healthcare Conference

NEW YORK, March 15, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer's 28th Annual Healthcare Conference, being held March 20-21, 2018 [...]

2018-03-15T08:50:34+00:00 Categories: 新闻通稿|Tags: |

Oramed Adds Two New Members to its Scientific Advisory Board

NEW YORK, Feb. 28, 2018  /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the additions of Drs. Robert Henry and Jane Reusch to its Scientific Advisory Board. Dr. [...]

2018-02-28T08:25:24+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension

JERUSALEM, Feb. 20, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming CODHy Conference, The 6th World Congress on Controversies [...]

2018-02-20T08:26:11+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at BIO CEO Investor Conference

JERUSALEM, Feb. 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 12-13, [...]

2018-02-06T08:26:59+00:00 Categories: 新闻通稿|Tags: |

Oramed Pharmaceuticals’ CEO Issues Letter to Shareholders

JERUSALEM, Jan. 19, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com) Dear Shareholders, All the hard work and dedication in 2017 has successfully positioned Oramed to initiate a U.S. based multicenter 90-day treatment study under a FDA IND focused on the lowering of [...]

2018-01-19T08:25:22+00:00 Categories: 新闻通稿|Tags: |

Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule

JERUSALEM, Nov. 14, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel's Ministry of Health has granted the Company approval to initiate an exploratory clinical study of its [...]

2017-11-14T08:02:09+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at the Diabetes Technology Meeting

JERUSALEM, October 24, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 17th Annual Diabetes Technology Meeting, November 2 to November 4, [...]

2017-10-24T09:26:58+00:00 Categories: 新闻通稿|Tags: |

Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists

JERUSALEM, Oct. 17, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the publication of a new paper co-authored by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, Dr. Roy Eldor, Dr. [...]

2017-10-17T08:41:11+00:00 Categories: 新闻通稿|Tags: |